James M. Daly

James M. Daly is a declared insider at 5 companies (senior executive); the most frequent names are Madrigal Pharmaceuticals, Inc., Acadia Pharmaceuticals Inc and Halozyme Therapeutics, Inc. Over a trading history stretching from 5 May 2021 to 1 October 2026, the count stands at 23 filings.

Sales make up the whole of the open-market record (2 sales, €979k). Outside the open market, there are 12 share grants and 9 option exercises.

The newest entry dates from 2 October 2026: a share grant, in Halozyme Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.